OPKO Health (NASDAQ:OPK – Get Free Report) and Super Nova Resources (OTCMKTS:SNRR – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk.
Risk & Volatility
OPKO Health has a beta of 1.51, meaning that its share price is 51% more volatile than the S&P 500. Comparatively, Super Nova Resources has a beta of -0.57, meaning that its share price is 157% less volatile than the S&P 500.
Institutional and Insider Ownership
64.6% of OPKO Health shares are held by institutional investors. 44.7% of OPKO Health shares are held by company insiders. Comparatively, 17.6% of Super Nova Resources shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| OPKO Health | 1 | 4 | 1 | 0 | 2.00 |
| Super Nova Resources | 0 | 0 | 0 | 0 | 0.00 |
OPKO Health currently has a consensus price target of $1.55, indicating a potential upside of 13.14%. Given OPKO Health’s stronger consensus rating and higher possible upside, equities analysts clearly believe OPKO Health is more favorable than Super Nova Resources.
Profitability
This table compares OPKO Health and Super Nova Resources’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| OPKO Health | -12.40% | -5.88% | -3.83% |
| Super Nova Resources | N/A | N/A | N/A |
Earnings & Valuation
This table compares OPKO Health and Super Nova Resources”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| OPKO Health | $606.90 million | 1.68 | -$225.68 million | ($0.09) | -15.22 |
| Super Nova Resources | N/A | N/A | N/A | N/A | N/A |
Super Nova Resources has lower revenue, but higher earnings than OPKO Health.
Summary
OPKO Health beats Super Nova Resources on 7 of the 10 factors compared between the two stocks.
About OPKO Health
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.
About Super Nova Resources
Super Nova Resources, Inc. provides employment screening and talent management software as a service. The company's employment screening services include assessment tests, background checks, drug and alcohol testing, and Form I-9 compliance. Its integrated talent management software suite consists of three modules for applicant tracking, onboarding, and performance management. The company's clients principally operate in markets, such as healthcare, staffing, transportation-logistics, and retail-hospitality. It delivers its services to approximately 1,000 clients in the United States. Super Nova Resources, through its division, Greenlink Interactive, also provides sales and marketing services to partner companies for a range of industries, venues, and customer types via its interactive technologies and distribution channels. The company develops business models for various sectors, products, and services, including home improvement products, wellness, apparel, real estate, housing, and gifts. It utilizes specialized marketing techniques in conjunction with proprietary Greenlink Interactive Video Assistance, Always-On, and Point-of-Decision Systems to market and sell products and services. In addition, Super Nova Resources has a joint venture agreement with Early Detect, Inc. to develop Live Interactive Point-of-Decision Systems to be deployed in retail locations. The company was formerly known as Navicus, Inc. and changed its name to Super Nova Resources, Inc. in November 2008. Super Nova Resources, Inc. was incorporated in 1965 and is based in Corona, California.
Receive News & Ratings for OPKO Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OPKO Health and related companies with MarketBeat.com's FREE daily email newsletter.
